AI주식인사이트AI Stock Insight
D

비보존 제약

082800KOSDAQ의약품 제조업

34.5 / 100

Reference Date: 2026-04-13

Financial Score5.0 / 40
News Sentiment17.5 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Plunged 19.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Bibozen Pharmaceuticals is a specialized pharmaceutical company primarily engaged in the manufacturing and sales of prescription and over-the-counter drugs, offering a wide range of products including cardiovascular medications, diabetes treatments, and analgesics. The company operates over 190 product items through diverse business activities such as CMO, OEM, and international exports, while focusing on the research and development of innovative new drugs.

Number of Employees

292people

Average Salary

52.8M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 14.804.0Point
PBR
2.63Industry Average 1.040.0Point

2.5x industry avg (risky)

ROE
-36.21Industry Average 4.420.0Point

Well below industry avg

Debt Ratio
20.79Industry Average 11.980.5Point

1.7x industry avg (risky)

Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.5 / 3

Avg ▼4.7% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼380.7% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -16.3% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 70

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 3,145Won52-week high 7,79252-week low 2,980
1-month return0.0Point

1m -19.87% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

13 totalPositive 0Neutral 13Negative 0
  • Neutral주요사항보고서(자기주식처분결정)2026-04-10
  • Neutral주식등의대량보유상황보고서(일반)2026-04-09
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-06
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-03
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-04-01